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ABSTRACT 
Objective: Statins display anti-inflammatory and antiepileptogenic properties in animal models, 
and may reduce the epilepsy risk in elderly humans; however, a possible modulating role on 
outcome in patients with status epilepticus (SE) has not been assessed.  
Methods: This cohort study was based on a prospective registry including all consecutive adults 
with incident SE treated in our center between April 2006 and September 2012. SE outcome was 
categorized at hospital discharge into ‘‘return to baseline’’, “new disability”, and ‘‘mortality’’. 
The role of potential predictors, including statins treatment on admission, was evaluated using a 
multinomial logistic regression model.  
Results: Among 427 patients identified, information on statins was available in 413 (97%). 
Mean age was 60.9 [± 17.8] years; 201 (49%) were women; 211 (51%) had a potentially fatal SE 
etiology; and 191 (46%) experienced generalized-convulsive or non-convulsive SE in coma. 
Statins (simvastatin, atorvastatin, or pravastatin) were prescribed prior to admission in 76 (18%) 
subjects, mostly elderly. While 208 (50.4%) patients returned to baseline, 58 (14%) died. After 
adjustment for established SE outcome predictors (age, etiology, SE severity score- STESS), 
statins correlated significantly with lower mortality (related risk ratio=0.38, p=0.046),.  
Conclusion: This study shows for the first time that exposure to statins before a SE episode is 
related to its outcome, suggesting a possible antiepileptogenic role. Other studies are needed to 
confirm this intriguing finding.  
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Introduction 
Status epilepticus represents an acute neurological condition with considerable morbidity and an 
estimated short-term mortality of up to 22% 1, 2. Several studies have shown that outcome is 
independently related to increasing age, underlying etiology, and SE severity 3-6, while the 
specific impact of antiepileptic treatment is debated 7. Moreover, the role of medications not 
related to seizure suppression has received scarce attention so far.  
Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) 
reductase, the key enzyme in cholesterol biosynthesis. They are usually prescribed in 
hypercholesterolemia, atherosclerosis diseases, and for secondary prevention of cardiovascular 
disease 8-10. Recently, statins potential neuroprotective, anti-inflammatory and antiexcitotoxic 
effects have been described in animal models of different neurological processes, such as 
multiple sclerosis, Parkinson’s and Alzheimer’s diseases, traumatic brain injury (TBI), and, 
particularly, epilepsy 11-15, where these compounds seem to decrease seizures severity and related 
hippocampal cell death in rodent models 16-19.  
Despite the wide prescription of statins, their potential effect in human epilepsy has been 
addressed in only two observational studies, which showed a protective role for the risk of 
developing epilepsy in elderly patients 20, 21. Nevertheless, to the best of our knowledge, their 
role in status epilepticus (SE) prognosis in humans has not been studied so far. The present 
analysis was designed to investigate the relationship of statins with SE outcome. 
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PATIENTS AND METHODS 
Patients 
This observational cohort study enrolled consecutive adults with an incident episode of SE, 
treated at our tertiary care center between April 1, 2006 and September 1, 2012 (77 months) and 
prospectively included in our registry 22. Subjects younger than 16 years, with post-anoxic SE, or 
with previous SE episodes were excluded. We retrospectively collected information (assessed 
through charts review) regarding different types and doses of statins administered on a daily 
basis before admission for the incident SE episode. This study was fully approved by the 
research ethics committee of the Canton of Vaud.  
Definition of variables  
As detailed previously 22, demographic data, time to treatment institution, and occurrence of 
previous seizures were prospectively collected at each SE admission for our SE registry. SE was 
defined as the occurrence of continuous epileptic seizures or recurrent seizures without recovery 
of consciousness, for >30 min (until 2008), and >5 min (since 2008), according to the 
operational definition 23. Seizure semiology was classified as simple partial, absence, generalized 
myoclonic, complex partial, generalized convulsive, or nonconvulsive SE in coma, defined by 
the worst clinical seizure type in a given SE episode. SE was diagnosed clinically, but in 
nonconvulsive episodes EEG confirmation was formally required. We further classified 
etiologies as «potentially fatal» if potentially leading to death independently of SE (e.g., acute 
large vessel ischemic stroke, acute cerebral hemorrhage, acute central nervous system (CNS) 
infection, severe systemic infection, malignant brain tumor, acquired immunodeficiency 
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syndrome (AIDS) with CNS complications, chronic renal failure requiring dialysis, systemic 
vasculitis, metabolic disturbance or acute intoxication sufficient to cause coma in the absence of 
SE, eclampsia). This approach has been shown by our and other groups to better account for 
outcome than the classical etiological categorization into acute symptomatic, remote 
symptomatic, progressive symptomatic, and idiophatic/cryptogenic 5, 24, 25. The validated 
prognostic score “STESS” (Status Epilepticus Severity Score), relying on age, previous seizure 
history, seizure type, and degree of consciousness impairment 6, was prospectively categorized 
as 0-2 (favorable outcome) vs. 3-6 (unfavorable outcome). At hospital discharge, we assesed 
three outcomes: return to baseline clinical conditions, survival with residual disability, or death.  
Procedures 
All subjects underwent electrolytic, metabolic, and hematologic work-up. Brain imaging 
(computed tomography scan and/or magnetic resonance imaging) and lumbar puncture were 
performed as needed. All patients had at least one EEG recording in the first 12-24 h after 
hospitalization. Follow-up studies were performed as clinically required. Patients were treated 
first-line with benzodiazepines, most frequently with 0.5-2 mg intravenous clonazepam. Second-
line treatment included intravenous phenytoin (typical loading dose of 20 mg/kg), valproate (20 
mg/kg), or levetiracetam (20-30 mg/kg). When the patient did not respond to the first and second 
line treatment, SE was considered as refractory, and its management was performed according to 
the predominant seizure type and the general clinical situation of the patient, ranging from 
controlled antiepileptic treatment escalation (both in dosage and number of compounds) without 
coma induction, to tracheal intubation and coma induction targeting electrographic burst-
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supression for at least 24 h before weaning the anesthetic medication over 12-24 h. In these 
cases, propofol, midazolam, and thiopental were used alone or in combination.  
Statistical analyses 
Data analysis was performed using STATA 12.1 (College Station, TX, USA). Data were 
summarized as mean (±sd) for continuous variables and as numbers (percentages) for categorical 
data. Univariate multinomial logistic regression was performed to assess the association of 
potential outcome predictors (age, gender, SE semiology, occurrence of previous seizures, 
potentially fatal etiology, STESS, SE duration shorter than 30 minutes, and previous statins 
treatment) to the SE outcome. The strength of the associations was measured using the RRR 
(Relative Risk Ratio), where the ‘‘return to baseline’’ group was fixed as the reference.  
Significant predictors at the level of 20% were used in a backward procedure to fit a multivariate 
model. 
 
 
RESULTS 
From a total of 515 SE episodes recorded during the study period, we identified 427 incident 
patients. In 413 of them (80% of total, 97% of the incident episodes), data regarding statin 
treatment on admission were available: mean age was 60.9 [± 17.8] years; 201 (49%) were 
women; 172 (42%) had a previous diagnosis of epilepsy; 249 (60%) presented an acute 
symptomatic etiology, and 211 (51%) a potentially fatal etiology. The duration of the episode 
was between 5-29 minutes in 37 (9%) patients. Regarding semiology, 5 (1%) experienced 
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absence SE, 1 (0.2%) myoclonic SE (in the context of genetic generalized epilepsy), 81 (20%) 
simple-partial SE, 135 (33%) complex-partial SE, 170 (41%) generalized-convulsive SE, and 21 
(5%) nonconvulsive SE in coma. Statins (simvastatin, atorvastatin and pravastatin) were 
prescribed before admission in 76 (18%) subjects. For details, see Figure 1. Regarding SE 
outcome, 208 (50%) patients returned to baseline clinical conditions, whereas 58 (14%) died. 
Table 1 illustrates the univariable analyses of potential outcome predictors: older age, the 
presence of previous seizures, a potentially fatal etiology, and STESS≥3 were significantly 
related to outcome (both new disability and mortality; p<0.001); while gender, SE semiology, 
and duration of the episodes (categorized at 30 minutes) were not. Of note, previous treatment 
with statins was not associated with a different outcome in univariable analysis. Older patients 
were clearly more likely to receive this type of drugs (p<0.001). After adjustment for age, 
previous seizures, potentially fatal etiology, and STESS, statins use was independently 
associated with a lower risk of mortality (RRR= 0.38, 95% Confidence interval (CI) [0.15-0.98], 
p=0.046), but not of new disability (RRR= 0.72, 95% CI [0. 4-1.36], p=0.29) (Table 2). Older 
age and potentially fatal etiology were independent predictors for both outcomes, while previous 
seizures were only related to a lower risk of new disability. A high STESS score was 
independently related to a higher mortality, but it was not associated to a lower disability. Of 
note, there was no interaction between statins and stroke as regards SE outcome. Figure 2 
illustrates that the association between age and mortality after a first episode of SE was 
maintained in patients exposed to statins, however at a lower occurrence rate. 
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DISCUSSION 
This study provides Class III evidence  that statins, usually prescribed for reducing 
cardiovascular risk, are significantly correlated with a lower risk of mortality after SE, following 
adjustment for the most important outcome predictors 3-5, 24.  
Only two human studies have examined the possible benefits of HMG-CoA inhibitors in 
modifying the risk of epilepsy so far. The rate of new-onset epilepsy in older veterans was 
lowered by statin prescription (OR 0.64, 95% CI 0.56–0.73), suggesting a possible target for 
prevention of geriatric epilepsy 20. Among a large cohort of cardiovascular patients who received 
a revascularization procedure, 217 cases with a diagnosis of epilepsy were matched to 2170 
controls by age and admission time; the adjusted risk ratio for epilepsy among statin users was 
0.65 (95% CI 0.46–0.92), whereas no benefit was found for non-statin cholesterol-lowering 
drugs, β-blockers, or angiotensin-converting enzyme inhibitors 21. Overall, these two congruent 
findings suggest a protective effect of statins for the risk of developing epilepsy. Our results 
therefore expand these observations in adults with incident SE. Statins use was only related to 
mortality but not to new disability: mortality after SE mostly relates to etiology and 
complications, and not to SE itself 3-5, it is therefore possible that statines also impacted on the 
the global health of acutely admitted patients. Furthermore, disability is not as a robust outcome 
as mortality, and is assessed at a variable time (hospital discharge), likely influencing the 
strengths of the found relationships.  
Several experimental studies have supported the antiepileptogenic properties of statins. 
Simvastatin, lovastatin and atorvastatin reduced the severity of kainite-induced-seizures and 
excitotoxicity in the hippocampus and limbic structures 16, 17, and atorvastatin also attenuated 
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kainate-induced hippocampal cellular death involving the Akt-phosphorylation pathway and 
glutamate transport modulation 18. An additive anticonvulsant effect of simvastatin, fluvastatin, 
lovastatin and atorvastatin, when co-administered with some antiepileptic compounds in the 
DBA/2 mice model of generalized tonic-clonic seizure has been reported 19. Our findings suggest 
a possible anti-epileptogenic mechanism of statins also in humans, which might be the 
consequence of anti-inflammatory properties 26, 27, in light of the increasing evidence of a link 
between inflammation and the epileptogenicity 28-30.  
This study has some limitations. Although our SE database is prospective, ensuring the best 
possible data quality for variables assessed acutely, data collection regarding previous statin 
treatment was retrospective; however, we were able to find detailed information for the vast 
majority of patients. The predictive models were not adjusted for medical comorbidities, 
although these show only a marginal added value in outcome prognostication 24. Indeed, our 
statistical model controlled for potential confounding by the most robust prognostic factors. We 
did not analyzed antiepileptic treatment, since on a subgroup of patients of the present cohort we 
recently showed that treatment appropriateness does not significantly influence clinical outcome 
7. Finally, statins were not analyzed separately regarding type and dose, due to the relatively low 
numbers in each group. Conversely, this study includes a large number of patients with SE 
diagnosis, and to the best of our knowledge it is the first addressing this question. Further studies 
are needed to confirm this potentially important clinical observation.  
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TABLES:  
Table 1. Summary description of potentially outcome predictors of disability or death in SE 
patients; univariable analyses (statistically significant factors in bold). (Abbrevations: N: 
Number of patients, RRR: Relative risk ratio, RRR-1: New disability vs. Return to baseline, 
RRR-2: Mortality vs Return to baseline, SD: standard deviation, F: female).  
 
 Return to baseline 
N (%) 
New 
disability 
N (%) 
Mortality 
N (%) 
RRR-1 RRR-2 P value-1 P value-2 
Total 208 (50) 147 (36) 58 (14) -- -- -- -- 
Age, mean (SD) 56.1 (18) 65.2 (16) 67.7 (16) 1.03 1.04 <0.001 <0.001 
Gender (F) 95 (46) 75 (51) 31 (53) 1.24 1.37 0.320 0.290 
Previous 
seizures 
124 (60) 34 (23) 14 (24) 0.21 0.22 <0.001 <0.001 
Semiology 
(Generalized 
convulsive or 
non-convulsive 
SE in coma) 
100 (46) 66 (45) 25 (43) 0.88 0.82 0.550 0.500 
Potentially 
fatal etiology 
68 (33) 96 (65) 47 (81) 3.87 8.79 <0.001 <0.001 
STESS, median 
(range) 
2 (0-5) 3 (0-6) 3 (1-6) 1.66 2.12 <0.001 <0.001 
SE Duration 
<30’ 
20 (10) 13 (9) 4 (7) 0.91 0.69 0.810 0.520 
Statins 
treatment on 
admission 
42 (20) 27 (18) 7 (12) 0.89 0.54 0.670 0.160 
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Table 2. Potential predictors of new disability or death in SE patients; results of the multinomial 
logistic model (statistically significant factors in bold).  (Abbrevations: RRR: Relative risk ratio, 
RRR-1: New disability vs. Return to baseline, RRR-2: Mortality vs. Return to baseline, CI: 
Confidence interval).  
 RRR-1 [95% CI] RRR-2 [95% CI] P value-1 P value-2 
Age  1.02 [1. 01-1.04] 1.04 [1. 01-1.06] 0.001 0.001 
Previous seizures  0.33 [0. 19-0.58] 0.54 [0. 25-1.18] <0.001 0.120 
Potentially fatal etiology  3.38 [2. 08-5.51] 8.7 [4.02-18.78] <0.001 <0.001 
STESS ≥3 1.45 [0. 82-2.56] 3.1 [1.31-7.3] 0.200 0.010 
Statins previous treatment 0.73 [0. 4-1.36] 0.38 [0. 15-0.98] 0.300 0.046 
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